Oxford Neurovascular and Neuroradiology Research Unit, Level 6, West Wing, John Radcliffe Hospital, Oxford UK.
Stroke. 2012 Oct;43(10):2544-50. doi: 10.1161/STROKEAHA.112.657254. Epub 2012 Jul 26.
We report the primary outcome of the Cerecyte Coil Trial, a randomized trial to determine whether polymer-loaded Cerecyte coils compared with Micrus bare platinum coils improved the proportion of patients with angiographic occlusion of the aneurysm at 6 months when assessed by a core laboratory. The secondary objectives were to compare the clinical outcomes and retreatment rates in the 2 groups.
Five hundred patients between 18 and 70 years of age with a ruptured or unruptured target aneurysm were randomized to be treated with either Cerecyte or bare platinum coils in 23 centers worldwide. Two hundred forty-nine patients were assigned to Cerecyte coils and 251 to bare platinum coils. Analysis was by intention to treat.
Four hundred ninety-four patients were eligible for analysis. Four hundred eighty-one patients underwent coil treatment of their aneurysm, 227 patients with recently ruptured aneurysms and 254 with unruptured aneurysms. Four hundred thirty-three follow-up angiograms were assessed by the core laboratory; 127 of 215 (59%) and 118 of 218 (54%) in the Cerecyte and bare platinum groups, respectively, fulfilled the trial prespecified definition of success, namely that the treated aneurysm showed complete angiographic occlusion, had stable neck remnant, or improved in angiographic appearance compared with the end-of-treatment angiogram (P=0.17). Late retreatment was performed in 25 of 452 (5.5%) patients, 17 (7.7%) Cerecyte versus 8 (3.5%) bare platinum (P=0.064; range, 4-34 months). The clinical outcomes did not differ between the groups.
There was no significant difference at 6 months in the angiographic outcomes between Cerecyte coils and bare platinum coils when assessed by the core laboratory. Clinical Trial Registration Information- URL: www.controlled-trials.com. Unique Identifier: ISRCTN82461286.
我们报告 Cerecyte 线圈试验的主要结果,这是一项随机试验,旨在确定与 Micrus 裸白金线圈相比,聚合物负载的 Cerecyte 线圈是否能在 6 个月时通过核心实验室评估改善动脉瘤血管闭塞的患者比例。次要目标是比较两组的临床结果和再治疗率。
500 名年龄在 18 至 70 岁之间的破裂或未破裂目标动脉瘤患者在全球 23 个中心被随机分配接受 Cerecyte 或裸白金线圈治疗。249 名患者被分配到 Cerecyte 线圈组,251 名患者被分配到裸白金线圈组。分析采用意向治疗。
494 名患者符合分析条件。481 名患者接受了动脉瘤线圈治疗,227 名患者为近期破裂动脉瘤,254 名患者为未破裂动脉瘤。核心实验室评估了 433 次随访血管造影;Cerecyte 组和裸白金组分别有 127 例(59%)和 118 例(54%)符合试验预先规定的成功定义,即治疗后的动脉瘤完全血管闭塞,瘤颈残留稳定,或与治疗结束时的血管造影相比有所改善(P=0.17)。452 名患者中有 25 名(5.5%)进行了晚期再治疗,Cerecyte 组 17 例(7.7%),裸白金组 8 例(3.5%)(P=0.064;范围,4-34 个月)。两组的临床结果没有差异。
在核心实验室评估时,Cerecyte 线圈和裸白金线圈在 6 个月时的血管造影结果没有显著差异。临床试验注册信息- URL:www.controlled-trials.com。独特标识符:ISRCTN82461286。